Advertisement

Autoantibodies to Myelin Basic Protein In Multiple Sclerosis

  • K. G. Warren
  • I. Catz

Abstract

Multiple sclerosis (MS) was initially described in the nineteenth century in Europe and subsequently in North America. The diary and letters of Sir Augustus Frederick d’Este (1794–1848), the grandson of George III of England and a cousin of Queen Victoria, illustrate the earliest personal description of this disease. Over a period of 28 years he experienced recurring symptoms including blurring of vision, numbness of limbs, loss of balance, bladder and bowel disturbances, staggering gait and finally paralysis, all highly characteristic of the clinical course of MS (21). The Parisian physician Jean Martin Charcot (1825–1893) and his colleague Vulpian are generally given the credit for bringing this unique disease to the attention of the medical community and separating it form the multitude of undifferentiated paralytic disorders of that era (16). Attempts to understand the etiology-pathogenesis of this disease must consider the following facts:
  1. (a)

    MS as a clinical-pathological entity has been known for close to 200 years and therefore its precipitating factor(s) must have been present for an equal period of time.

     
  2. (b)

    MS is an inflammatory-demyelinating disease with associated gliosis and relative neuronal-axonal sparing, which is restricted to the central nervous system (CNS) of human beings.

     

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Myelin Basic Protein Optic Neuritis Albumin Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams JM, Imagawa DT: Measles antibodies in multiple sclerosis. Proc Soc Exp Bio Med 111:562–566, 1962Google Scholar
  2. 2.
    Alvord EC, Shaw CM, Hruby S, Sites L, Slimp JC: The onset of experimental allergic encephalomyelitis as defined by clinical, electrophysiological and immunochemical studies. In Alvord CE, Kies MW, Suckling AJ (eds): EAE a useful model for MS. Alan R Liss Inc, New York, 1984, pp 461–466Google Scholar
  3. 3.
    Braun PE, Brostoff SW: Proteins of myelin. In Morell P (ed): Myelin, Plenum Press, New York, 1977, pp 201–230Google Scholar
  4. 4.
    Brostoff SW, Eylar EH: The proposed amino acid sequence of the Pl protein of rabbit sciatic nerve myelin. Arch Biochem Biophys 153:590–598, 1972PubMedCrossRefGoogle Scholar
  5. 5.
    Carnegie R: Amino acid sequence of the encephalitogenic protein of human myelin. Biochem J 123:57–67, 1971PubMedGoogle Scholar
  6. 6.
    Carswell R: Pathological anatomy: Illustrations on the elementary forms of the disease. Longman, Orwe, Brown, Green and Longman, London, 1838Google Scholar
  7. 7.
    Catz I, Warren KG: Intrathecal synthesis of autoantibodies to myelin basic protein in multiple sclerosis. Can J Neurol Sci 13:21–24, 1986PubMedGoogle Scholar
  8. 8.
    Chou CHJ, Tourtellotte WW, Kibler RF: Failure to detect antibodies to myelin basic protein or its peptic fragments in CSF of patients with MS. Neurology 33:24–28, 1983PubMedGoogle Scholar
  9. 9.
    Cohen SR, Herndon RM, McKhann GM: Radioimmunoassay of myelin basic protein in spinal fluid. N Engl J Med 295:1455–1457, 1976PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen SR, Brooks BR, Herndon RM, McKhann GM: A diagnostic index of active demyelination: Myelin basic protein in cerebrospinal fluid. Ann Neurol 8:25–31, 1980PubMedCrossRefGoogle Scholar
  11. 11.
    Colby SP, Sheremat W, Bain B, Eylar EH: Cellular hypersensitivity in attacks of MS. 1. A comparative study of migration inhibitory factor production and lymphoblastic transformation in response to MBP in multiple sclerosis. Neurology 27:132–139, 1977PubMedGoogle Scholar
  12. 12.
    Coyle PK: CSF immune complexes in multiple sclerosis. Neurology 35:429–432, 1985PubMedGoogle Scholar
  13. 13.
    Cruveilhier J: Anatomie pathologique du corps humain. Bailliere, Paris, 1842Google Scholar
  14. 14.
    Dasgupta MK, Catz I, Warren KG: Myelin basic protein: A component of circulating immune complexes in multiple sclerosis. Can J Neurol Sci 10:239–243, 1983PubMedGoogle Scholar
  15. 15.
    Dawson JW: The histology of disseminated sclerosis. Published as part of: Transactions of the Royal Society of Edinburgh, 1916Google Scholar
  16. 16.
    Dejone RN: Multiple sclerosis: History, definition and general considerations. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology, North Holland, Amsterdam, 1970, vol 9, pp 45–62Google Scholar
  17. 17.
    Diebler GE, Martenson RE, Kies MW: Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 2:139–165, 1972CrossRefGoogle Scholar
  18. 18.
    Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM: Antibodies to glycosphingolipids in patients with MS and SLE. J Immun 23:1793–1797, 1984Google Scholar
  19. 19.
    Esiri MM: Immunoglobulin containing cells in multiple sclerosis plaques, Lancet 11:478–481, 1977CrossRefGoogle Scholar
  20. 20.
    Esiri MM: Multiple sclerosis: A quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropath Appl Neurobiol 6:9–21, 1980CrossRefGoogle Scholar
  21. 21.
    Firth D: The case of Augustus d’Este, Cambridge University Press, London, 1948Google Scholar
  22. 22.
    Hershey LA, Trotter JL: The use and abuse of the CSF IgG profile in the adult: A practical evaluation. Ann Neurol 8:426–434, 1980PubMedCrossRefGoogle Scholar
  23. 23.
    Hunter WM, Greenwood FC: Preparation of I131 labelled human growth hormone of high specific activity. Nature 195:495–496, 1980Google Scholar
  24. 24.
    Johnson KP: CSF and blood assays of diagnostic usefulness in MS. Neurology 30:106–109, 1980PubMedGoogle Scholar
  25. 25.
    Kabat EA, Glusman M, Knaub V: Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 4:653–662, 1948PubMedCrossRefGoogle Scholar
  26. 26.
    Leibowitz S, Hughes RAC: Multiple sclerosis. In Immunology of the Nervous System. Arnold E (ed) London 1983, pp 185–214Google Scholar
  27. 27.
    Link H, Tibbling G: Principles of albumin and IgG synthesis in neurological disorders. II. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 37:397–401, 1977PubMedCrossRefGoogle Scholar
  28. 28.
    Lumsden CE: The immunogenesis of the multiple sclerosis plaque. Brain Res 28:365–370, 1971PubMedCrossRefGoogle Scholar
  29. 29.
    Mehta PD, Frisch S, Thormar H, Tourtellotte WW, Wisniewski HM: Bound antibody in multiple sclerosis brains. J Neurol Sci 49:91–98, 1981PubMedCrossRefGoogle Scholar
  30. 30.
    McAlpine D, Lumsden CE, Acheson ED: Multiple sclerosis: Cause and prognosis. In Multiple sclerosis: A reappraisal. Churchill Livingstone, London, 1972, pp 214–220Google Scholar
  31. 31.
    Norrby E, Link H, Olsson JE: Measles virus antibodies in multiple sclerosis. Arch Neurol 30:285–292, 1974PubMedGoogle Scholar
  32. 32.
    Panitch HS, Hooper CS, Johnson KP: CSF antibody of myelin basic protein: Measurement in patients with MS and SSPE. Arch Neurol 37:206–209, 1980PubMedGoogle Scholar
  33. 33.
    Prineas JW, Connell F: The fine structure of chronically active multiple sclerosis plaques. Neurology 28:68–75, 1978PubMedGoogle Scholar
  34. 34.
    Prineas JW, Wright RG: Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 38:409–421, 1978PubMedGoogle Scholar
  35. 35.
    Rivers TM, Sprunt DH, Berry GP: Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58:39–53, 1933PubMedCrossRefGoogle Scholar
  36. 36.
    Rostami A, Eccleston PA, Silberberg DH, Manning MC, Burns JB, Lipak RP: Absence of antibodies to galactocerebroside in the sera and CSF of human demyelinating disorders. Neurology 33:130, 1983Google Scholar
  37. 37.
    Ryland H, Mork S, Matre R: In situ characterization of mononuclear cell infiltrates in lesions of multiple sclerosis. Neuropath Appl Neurobiol 8:403–411, 1982CrossRefGoogle Scholar
  38. 38.
    Salmi AA: Viral antibodies in multiple sclerosis. In Problems in Multiple Sclerosis Research, Pedersen E, Clausen J and Oades L (eds) FADL’s Forlag, Copenhagen, 1983, pp 368–370Google Scholar
  39. 39.
    Schumacher GA, Beebe G, Kibler RE: Problems of experimental trials of therapy in MS. Ann NY Acad Sci 122:552–568, 1965CrossRefGoogle Scholar
  40. 40.
    Steck AJ, Link H: Antibodies against oligodendrocytes in serum and CSF in MS and other neurological diseases. I125 protein A studies. Acta Neurol Scand 69:81–89, 1984Google Scholar
  41. 41.
    Tibbling G, Link H, Ohlman S: Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37:385–390, 1977PubMedCrossRefGoogle Scholar
  42. 42.
    Tourtellotte WW: Multiple sclerosis cerebrospinal fluid. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology, North Holland, Amsterdam, 1970, vol 9, pp 324–383Google Scholar
  43. 43.
    Tourtellotte WW: On cerebrospinal fluid IgG quotients in multiple sclerosis and other diseases. J Neurol Sci 10:279–304, 1970PubMedCrossRefGoogle Scholar
  44. 44.
    Tourtellotte WW, Ma B: Multiple sclerosis: The blood-brain barrier and the measurement of de novo central nervous system IgG synthesis. Part II. Neurology (NY) 28:76–83, 1978Google Scholar
  45. 45.
    Tourtellotte WW: The CSF in MS. In Koetsier JC (ed): Handbook of Clinical Neurology: Demyelinating diseases, North Holland, Amsterdam, 1985, vol 3, pp 79–130Google Scholar
  46. 46.
    Traugott W, Stone SH, Raine CS: Chronic relapsing experimental allergic encephalomyelitis. J Neurol Sci 41:17–29, 1979PubMedCrossRefGoogle Scholar
  47. 47.
    Vartdal F, Vandvik B, Norrby E: Viral and bacterial antibody responses in MS. Ann Neurol 8:255, 1980CrossRefGoogle Scholar
  48. 48.
    Wajgt A, Gorny M: CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis — evidence of the intrathecal production of antibodies. Acta Neurol Scand 68:337–343, 1983PubMedCrossRefGoogle Scholar
  49. 49.
    Walsh JM, Tourtellotte WW: The cerebrospinal fluid in multiple sclerosis. In Hallpike JF, Adams CWM, Tourtellotte WW (eds): Multiple sclerosis. Williams & Williams, Baltimore, 1982, pp 275–358.Google Scholar
  50. 50.
    Walsh MJ, Tourtellotte WW: IgG, IgM and IgA temporal clonal stability in multiple sclerosis. Neurology 33 (suppl 2):123, 1983Google Scholar
  51. 51.
    Warren KG, Catz I: An investigation of the relationship between cerebrospinal fluid myelin basic protein levels and IgG measurements in multiple sclerosis patients. Ann Neurol 17:475–480, 1985PubMedCrossRefGoogle Scholar
  52. 52.
    Warren KG, Catz I: Diagnostic value of cerebrospinal fluid anti-myelin basic protein in multiple sclerosis patients. Ann Neurol 20:20–25, 1987CrossRefGoogle Scholar
  53. 53.
    Warren KG, Catz I: A correlation between CSF myelin basic protein and anti-myelin basic protein in multiple sclerosis patients. Ann Neurol 21:183–189, 1987PubMedCrossRefGoogle Scholar
  54. 54.
    Whitaker JN: The antigenicity of myelin basic protein: Production of antibodies to encephalitogenic protein with DNA-encephalitogenic protein complexes. J Im Neurol 144:823–900, 1975Google Scholar
  55. 55.
    Whitaker JN: Myelin encephalitogenic protein fragments in the cerebrospinal fluid of persons with multiple sclerosis. Neurology 27:911–920, 1977PubMedGoogle Scholar
  56. 56.
    Whitaker JN, Lisak RP, Bashir RM et al: Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol 7:58–64, 1978CrossRefGoogle Scholar
  57. 57.
    Wisniewski HM, Bloom BR: Experimental allergic optic neuritis in the rabbit: A new model to study primary demyelinating diseases. J Neurol Sci 24:257–263, 1975PubMedCrossRefGoogle Scholar
  58. 58.
    Wisniewski HM: Morphogenesis of the demyelinating process. In Davidson AN, Humphrey JH, Liversedge LA, McDonald WI, Porterfield JS (eds): Multiple Sclerosis Research, HMSO, London, 1975, pp 132–141Google Scholar
  59. 59.
    Wisniewski HM, Keith AB: Chronic relapsing experimental allergic encephalomyelitis: An experimental model of multiple sclerosis. Ann Neurol 1:144–148, 1977PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • K. G. Warren
    • 1
  • I. Catz
    • 1
  1. 1.Multiple Sclerosis Care and Research Clinic Division of NeurologyUniversity of AlbertaEdmontonCanada

Personalised recommendations